Urinary LAM grade, culture positivity, and mortality among HIV-infected South African out-patients
Authors:
- 1 November 2018
- journal article
- research article
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 22 (11) , 1366-1373
Abstract
SETTING: Four ambulatory clinics in Durban, South Africa. OBJECTIVE: To test the relationships of patient characteristics, time to mycobacterial culture positivity, and mortality with urinary lipoarabinomannan (LAM) grade category. DESIGN: Newly diagnosed human immunodeficiency virus (HIV) infected adults were screened for tuberculosis (TB) using sputum culture, tested for urinary LAM, and followed for up to 12 months. We performed multivariable ordinal logistic regression of risk factors for low (1 or 2) or high (3, 4, or 5) LAM grade. We used adjusted Cox regression models to determine the hazard ratios of time to culture positivity and death. RESULTS: Among 683 HIV-infected adults, median CD4 count was 215 cells/mm3 (interquartile range 86–361 cells/mm3), 17% had culture-confirmed TB, and 11% died during follow-up. Smoking, tachycardia (pulse > 100 beats/minute), CD4 count < 100 cells/mm3, and TB culture positivity were each associated with higher LAM grade. In multivariate models, a high urine LAM grade was associated with four-fold increased hazard of culture positivity (P = 0.001) and two-fold increased hazard of mortality (P = 0.02). Among patients treated for TB, these associations were no longer statistically significant. CONCLUSION: In this population, a higher urine LAM grade was associated with shorter time to culture positivity and mortality; however, these associations were not present for those starting anti-tuberculosis treatment.Keywords
This publication has 25 references indexed in Scilit:
- Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art reviewBMC Medicine, 2013
- HIV-associated tuberculosis: relationship between disease severity and the sensitivity of new sputum-based and urine-based diagnostic assaysBMC Medicine, 2013
- A randomized trial to optimize HIV/TB care in South Africa: design of the Sizanani trialBMC Infectious Diseases, 2013
- Clinical significance of lipoarabinomannan detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosisAIDS, 2012
- Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art reviewBMC Infectious Diseases, 2012
- Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patientsEuropean Respiratory Journal, 2012
- Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational StudiesPLOS Medicine, 2011
- Quantitative Analysis of a Urine-Based Assay for Detection of Lipoarabinomannan in Patients with TuberculosisJournal of Clinical Microbiology, 2010
- Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settingsThe Lancet Infectious Diseases, 2009
- Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changesThe Lancet, 2007